Dr. Michael R. Fine, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 362
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Michigan Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MI license 4301087862
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Trinity Health Ann Arbor Hospital Ann Arbor, MI
- St Joe Mercy Hospital System Livonia Livonia, MI
- Trinity Health Oakland Hospital Pontiac, MI
- Trinity Health Livingston Hospital Howell, MI
Medical groups
- Iha Health Services Corporation (1,168 clinicians)
- Huron Gastroenterology Associates PC (99 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 362
- Services billed
- 7,289
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 100 | 98 |
| Established patient office or other outpatient visit, 30-39 minutes | 77 | 63 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 65 | 15 |
| Biopsy of large bowel using a flexible endoscope | 37 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 23 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 35 | 35 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 30 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 24 |
| Ultrasound scan of organ tissue for measuring elasticity | 20 | 20 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Ypsilanti, MI | 153 |
| Omeprazole Other prescribers in Ypsilanti, MI | 89 |
| Pantoprazole Sodium Other prescribers in Ypsilanti, MI | 58 |
| Mesalamine Other prescribers in Ypsilanti, MI | 45 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Ypsilanti, MI | 39 |
| Ursodiol Other prescribers in Ypsilanti, MI | 30 |
| Carvedilol Other prescribers in Ypsilanti, MI | 30 |
| Balsalazide Disodium | 28 |
| Colestipol Hcl Other prescribers in Ypsilanti, MI | 27 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $1,818 in total to this clinician.
| Genzyme Corporation | $1,390 |
|---|---|
| Pfizer Inc. | $400 |
| Regeneron Healthcare Solutions, Inc. | $27.81 |
| Consulting Fee | $1,790 |
|---|---|
| Food and Beverage | $27.81 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Feb 14, 2025 | Consulting Fee | $1,390 |
| Pfizer Inc. Mar 3, 2025 | Consulting Fee | $400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $99,317 in research payments for these studies, mostly to the institutions running them.
- A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Ipsen Bioscience Inc. · Completed · NCT06383403 - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Ipsen Bioscience Inc. · Active, not recruiting · NCT05627362
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.